Brokerages Set Roivant Sciences Ltd. (NASDAQ:ROIV) PT at $17.10

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) have been given an average rating of “Moderate Buy” by the ten brokerages that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $17.10.

A number of brokerages have issued reports on ROIV. HC Wainwright restated a “buy” rating and set a $18.00 target price on shares of Roivant Sciences in a research report on Monday, August 19th. Cantor Fitzgerald restated an “overweight” rating on shares of Roivant Sciences in a research report on Tuesday, June 18th. Finally, Piper Sandler lifted their target price on shares of Roivant Sciences from $20.00 to $22.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 10th.

Institutional Investors Weigh In On Roivant Sciences

A number of institutional investors have recently bought and sold shares of the stock. Mutual of America Capital Management LLC grew its holdings in Roivant Sciences by 0.4% in the second quarter. Mutual of America Capital Management LLC now owns 327,079 shares of the company’s stock valued at $3,457,000 after purchasing an additional 1,142 shares during the period. Acadian Asset Management LLC grew its holdings in Roivant Sciences by 23.2% in the second quarter. Acadian Asset Management LLC now owns 8,510 shares of the company’s stock valued at $89,000 after purchasing an additional 1,603 shares during the period. nVerses Capital LLC purchased a new stake in Roivant Sciences in the second quarter valued at approximately $34,000. Headlands Technologies LLC purchased a new stake in Roivant Sciences in the fourth quarter valued at approximately $36,000. Finally, DNB Asset Management AS grew its holdings in Roivant Sciences by 6.4% in the second quarter. DNB Asset Management AS now owns 56,022 shares of the company’s stock valued at $592,000 after purchasing an additional 3,386 shares during the period. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Roivant Sciences Stock Down 0.2 %

Shares of NASDAQ ROIV opened at $11.75 on Friday. The company has a quick ratio of 27.91, a current ratio of 27.91 and a debt-to-equity ratio of 0.05. Roivant Sciences has a 52 week low of $8.24 and a 52 week high of $13.24. The firm has a 50-day moving average price of $11.14 and a 200 day moving average price of $11.01. The stock has a market capitalization of $8.68 billion, a price-to-earnings ratio of 2.32 and a beta of 1.24.

Roivant Sciences (NASDAQ:ROIV) last announced its earnings results on Thursday, August 8th. The company reported $0.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.33. The company had revenue of $55.10 million during the quarter, compared to analysts’ expectations of $30.72 million. Roivant Sciences had a net margin of 2,991.75% and a negative return on equity of 17.23%. The firm’s quarterly revenue was up 155.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.38) earnings per share. Equities research analysts anticipate that Roivant Sciences will post -1.14 EPS for the current fiscal year.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.